newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial

Seventh patient of the trial at the second cohort SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative